Project Management (PM) and Project Portfolio Management (PPM)

Pharmaceutical and Biotechnology Companies are significantly under pressure, more than ever. The competitive pressure is increasing, especially with many good generics in the market;  the Regulatory and Compliance requirements growing every day, with a significant raise in the post-approval commitments for clinical trials; the prices of all drugs are under deep scrutiny;  the expected differentiation from established Standards of Care (SoC) becoming more and more critical. In addition, in recent years, the R&D productivity has been going down significantly: costs, cycle times and attrition rate continue to grow, while revenues from new products after launch are going down.  In this challenging environment PM and PPM can really make a difference! They can improve significantly the efficiency and effectiveness of R&D;  they can also significantly contribute to the change in culture that will allow better financial allocation of resources and better risk management in R&D. Finally, a customer-oriented PM, especially focused on payers’ needs, will ensure better revenue flow from the launch of new products. The ROI for new medicines must improve and PM can be instrumental in this endeavor.